(Q34172753)
Statements
1 reference
Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study (English)
1 reference
John R Mackey
1 reference
Agnieszka Jagiełło-Gruszfeld
1 reference
Emilio Alba
1 reference
Janusz Rolski
1 reference
Sara Hurvitz
1 reference
Matthieu Rupin
1 reference
Henri Roche
1 reference
Tamas Pinter
1 reference
John Crown
1 reference
M John Kennedy
1 reference
Frank Priou
1 reference
Encarna Adrover
1 reference
Istvan Lang
1 reference
Manuel Ramos
1 reference
Jean Latreille
1 reference
Raymond Snyder
1 reference
Sachin Almel
1 reference
Montserrat Munoz
1 reference
Rebecca Moroose
1 reference
Ana Baños
1 reference
Henry Adewoye
1 reference
Yong-Jiang Hei
1 reference
Mary-Ann Lindsay
1 reference
David Cabaribere
1 reference
Yasmin Lemmerick
1 reference
TRIO 010 investigators
1 reference
21 March 2011
1 reference
1 reference
12
1 reference
369-376
1 reference
Identifiers
1 reference
1 reference